Astellas Forms Patient Experience Organization
By

By
Astellas has created a new department in the Americas that will formally build on efforts to ensure that “the voice of the patient” is incorporated across all facets of the…

GSK to Close Australian Plant
By

By
GlaxoSmithKline Consumer Healthcare, a GlaxoSmithKline business unit, announced that it will close its manufacturing facility at Ermington, Australia, a suburb northwest of Syndey, in 2020. The company said that decision…

US PTO Denies Review of Formulation Patent for Biosimilar of AbbVie’s Humira
By

By
Coherus BioSciences, headquartered in Redwood City, California and focused on biosimilar therapeutics, has received a decision from the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark…

Mylan Submits Filing of Biosimilar Herceptin to FDA
By

By
Mylan, with its partner Biocon, a Bangalore, India-based biotechnology company, have submitted Mylan’s biologics license application to the US Food and Drug Administration (FDA) for MYL-1401O, a proposed biosimilar of…

Merck KGaA Investing $275 Million in Pharma Manufacturing and Life Sciences Business in China
By

By
Merck KGaA has inaugurated its EUR 170 million ($189 million) pharmaceutical plant in Nantong, China, which will produce pharmaceuticals on China’s Essential Drug List, a colleciton of drugs chosen by…

Lonza Opens Drug Product Service Laboratories
By

By
Lonza held a grand opening of its pharmaceutical drug product services laboratories in the Stücki Science Park in Basel, Switzerland. Scientists in the new 1,300-square-meter facility will focus initially on…

EMA Accepts Mylan’s Filing for Biosimilar of Sanofi’s Lantus Insulin Analog
By

By
Mylan and Biocon, a biopharmaceutical company headquarterd in Bangalore, India, report that the European Medicines Agency has accepted for review Mylan’s marketing authorization application for insulin glargine, a long-acting insulin…

Ashland Opens Excipient Manufacturing Facility in China; Upgrades Tech Center
By

By
Ashland has opened a new manufacturing facility for excipients in Nanjing, China. With the new facility, Ashland can supply functional excipient technologies to manufacturers of oral pharmaceuticals as well as…

Lonza, Clovis in Cancer-Drug Supply Pact
By

By
Lonza has formed a long-term commercial supply agreement with Clovis Oncology, a Boulder, Colorado-based biopharmaceutical company, for the manufacture of Clovis’ rucaparib, a development-stage poly ADP-ribose polymerase (PARP) inhibitor. The…

GE Healthcare Expands Single-use Manufacturing Capabilities
By

By
GE Healthcare’s Life Sciences business has announced a $7 million expansion project at its single-use technology manufacturing facility in Westborough, Massachusetts. The expanded site will manufacture a range of single-use…